JP2013527164A5 - - Google Patents

Download PDF

Info

Publication number
JP2013527164A5
JP2013527164A5 JP2013506767A JP2013506767A JP2013527164A5 JP 2013527164 A5 JP2013527164 A5 JP 2013527164A5 JP 2013506767 A JP2013506767 A JP 2013506767A JP 2013506767 A JP2013506767 A JP 2013506767A JP 2013527164 A5 JP2013527164 A5 JP 2013527164A5
Authority
JP
Japan
Prior art keywords
dosage form
polyoxyethylene
tadalafil
citrate
ester
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013506767A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013527164A (ja
Filing date
Publication date
Priority claimed from US13/079,348 external-priority patent/US20110263606A1/en
Application filed filed Critical
Publication of JP2013527164A publication Critical patent/JP2013527164A/ja
Publication of JP2013527164A5 publication Critical patent/JP2013527164A5/ja
Pending legal-status Critical Current

Links

JP2013506767A 2010-04-26 2011-04-22 タダラフィルを含む固体経口剤形 Pending JP2013527164A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US32796910P 2010-04-26 2010-04-26
US61/327,969 2010-04-26
US13/079,348 US20110263606A1 (en) 2010-04-26 2011-04-04 Solid oral dosage forms comprising tadalafil
US13/079,348 2011-04-04
PCT/IB2011/000882 WO2011135426A1 (en) 2010-04-26 2011-04-22 Solid oral dosage forms comprising tadalafil

Publications (2)

Publication Number Publication Date
JP2013527164A JP2013527164A (ja) 2013-06-27
JP2013527164A5 true JP2013527164A5 (https=) 2014-04-10

Family

ID=44816306

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013506767A Pending JP2013527164A (ja) 2010-04-26 2011-04-22 タダラフィルを含む固体経口剤形

Country Status (5)

Country Link
US (2) US20110263606A1 (https=)
EP (1) EP2563346A4 (https=)
JP (1) JP2013527164A (https=)
CA (1) CA2797444A1 (https=)
WO (1) WO2011135426A1 (https=)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110136815A1 (en) 2009-12-08 2011-06-09 Horst Zerbe Solid oral film dosage forms and methods for making same
US10610528B2 (en) 2009-12-08 2020-04-07 Intelgenx Corp. Solid oral film dosage forms and methods for making same
GB2497728A (en) 2011-12-14 2013-06-26 Londonpharma Ltd Statin formulations for transmucosal delivery
GB2497933B (en) * 2011-12-21 2014-12-24 Londonpharma Ltd Drug delivery technology
WO2014092661A1 (en) * 2012-01-18 2014-06-19 Mahmut Bilgic Particulate formulations of tadalafil in effervescent form
WO2013109221A1 (en) * 2012-01-18 2013-07-25 Mahmut Bilgic New effervescent formulations comprising sweetener composition
US20150216798A1 (en) * 2012-08-17 2015-08-06 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Novel orally administered pharmaceutical formulations
US20150320677A1 (en) * 2012-08-17 2015-11-12 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Effervescent tablet formulations of dapoxetine and a pde5 inhibitor
US20150202168A1 (en) * 2012-08-17 2015-07-23 Sanovel llac Sanayi Ve Ticaret Anonim Sirketi Oral film formulations comprising dapoxetine and tadalafil
US20150231092A1 (en) * 2012-08-17 2015-08-20 Sanovell IIac Sanayi Ve Ticaret Anonim Sirketi Novel effervescent sachet formulations of dapoxetine and a pde5 inhibitor
US11116769B2 (en) 2013-04-11 2021-09-14 Ctc Bio, Inc. Tadalafil free base-containing film dosage form containing polyethylene glycol-based polymer and/or vinyl pyrrolidone-based polymer as dispersion stabilizer
CN105209025B (zh) * 2013-04-11 2019-06-18 西梯茜生命工学股份有限公司 包括聚乙二醇类聚合物和/或乙烯基吡咯烷酮类聚合物作为分散稳定剂的含他达拉非游离碱的膜剂形式
KR102239291B1 (ko) * 2013-06-28 2021-04-14 한미약품 주식회사 타다라필 또는 이의 약학적으로 허용가능한 염을 포함하는 저작정 제제
RU2016106907A (ru) * 2013-07-31 2017-09-01 Интелдженкс Корп. Мгновенно смачивающаяся пероральная пленочная лекарственная форма без поверхностно-активного вещества или полиспирта
KR20150138671A (ko) * 2014-06-02 2015-12-10 에스케이케미칼주식회사 타달라필을 함유하는 구강 붕해 필름 및 이의 제조방법
RU2681936C2 (ru) * 2014-06-24 2019-03-14 Усин Лаботтас Ко., Лтд. Орально распадающийся пленочный препарат, содержащий тадалафил, и способ его приготовления
KR101538985B1 (ko) * 2014-09-02 2015-07-24 주식회사 서울제약 타다라필 구강붕해필름 및 이의 제조방법
CZ2016570A3 (cs) * 2016-09-15 2018-03-28 Zentiva, K.S. Stabilní kompozice ODF obsahující těžce rozpustné terapeutické činidlo
CZ2017781A3 (cs) * 2017-12-05 2019-06-12 Zentiva, K.S. Těžko rozpustné terapeutická činidla,která patřící do BCS skupiny II nebo IV, suspendovaná v kapalné formulaci a/nebo v konečné nanovláknité struktuře
WO2019154896A1 (de) * 2018-02-07 2019-08-15 Sapiotec Gmbh Pharmazeutische formulierungen, verfahren zum herstellen einer pharmazeutischen formulierung sowie ein arzneimittel umfassend eine solche
CN109157520B (zh) * 2018-09-07 2021-04-02 苏州科技城医院 他达拉非片剂及其制备方法
US10828254B2 (en) 2018-09-28 2020-11-10 Intelgenx Corp. Oral film formulation for modulating absorption profile
US12303501B2 (en) 2018-11-05 2025-05-20 Intelgenx Corp. Lipophilic active oral film formulation and method of making the same
US12440472B2 (en) 2021-06-16 2025-10-14 Intelgenx Corp. Stable tryptamine oral films
WO2023232215A1 (en) * 2022-06-02 2023-12-07 Rontis Hellas S.A. Improved pharmaceutical composition containing tadalafil and process for the preparation thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19646392A1 (de) * 1996-11-11 1998-05-14 Lohmann Therapie Syst Lts Zubereitung zur Anwendung in der Mundhöhle mit einer an der Schleimhaut haftklebenden, Pharmazeutika oder Kosmetika zur dosierten Abgabe enthaltenden Schicht
ES2187234A1 (es) * 1999-04-30 2003-05-16 Lilly Icos Llc Forma de dosificacion oral para tratar la disfuncion sexual.
CA2612917A1 (en) * 2005-06-23 2007-01-04 Schering Corporation Rapidly absorbing oral formulations of pde5 inhibitors
CN101304974A (zh) * 2005-11-08 2008-11-12 辉瑞有限公司 吡唑衍生物和它们的医药用途
US9532945B2 (en) * 2006-04-04 2017-01-03 Kg Acquisition Llc Oral dosage forms including an antiplatelet agent and an enterically coated acid inhibitor
KR101140110B1 (ko) * 2006-07-07 2012-06-04 테바 파마슈티컬 인더스트리즈 리미티드 타달라필 및 하나 이상의 담체를 포함하는 고체 조성물
US20090098211A1 (en) * 2007-04-25 2009-04-16 Ilan Zalit Solid dosage forms
US20080292683A1 (en) * 2007-05-24 2008-11-27 Monosolrx, Llc. Film shreds and delivery system incorporating same
DE102007028869A1 (de) * 2007-06-22 2008-12-24 Ratiopharm Gmbh Verfahren zur Herstellung eines Arzneimittels enthaltend Tadalafil
US20090047330A1 (en) * 2007-08-17 2009-02-19 Ramesh Bangalore Oral fast dissolving films for erectile dysfunction bioactive agents
WO2009052421A1 (en) * 2007-10-19 2009-04-23 Innozen, Inc. Composition for administering an active ingredient and method for making and using the same
KR101074271B1 (ko) * 2009-06-25 2011-10-17 (주)차바이오앤디오스텍 불쾌한 맛을 효과적으로 은폐한 경구용 속용 필름

Similar Documents

Publication Publication Date Title
JP2013527164A5 (https=)
US20110263606A1 (en) Solid oral dosage forms comprising tadalafil
JP2015531377A5 (https=)
EP3431075A1 (en) Edaravone dosage form
JP2012025755A5 (https=)
FI2346495T4 (fi) Farmaseuttinen formulaatio 514
JP2017536398A5 (https=)
JP2007528388A5 (https=)
JP2015527395A5 (https=)
RU2015154403A (ru) Офтальмическая наноэмульсионная композиция, содержащая циклоспорин и способ ее получения
JP2013529665A5 (https=)
JP2015504924A5 (https=)
RU2013126259A (ru) Фармацевтическая композиция таксоидов
AR103653A1 (es) Complejos de acetato de abiraterona, proceso para prepararlos y composiciones farmacéuticas que los contienen
RU2017101833A (ru) Орально распадающийся пленочный препарат, содержащий тадалафил, и способ его приготовления
JP2015516418A5 (https=)
JP2017508802A5 (https=)
JP2014503479A (ja) アリピプラゾール組成物及びその経皮送達のための方法
RU2017142563A (ru) Твердые дисперсии q10
WO2017037647A1 (en) Stable pharmaceutical compositions of abiraterone
JP2013525485A5 (https=)
WO2016163403A1 (ja) 経口フィルム製剤
RU2014101990A (ru) Жидкая фармацевтическая композиция, включающая нитизинон
HRP20151051T1 (hr) Formulacije src/abl inhibitora
AR078785A1 (es) Formulaciones de bazedoxifeno con antioxidantes